Logo: to the web site of Uppsala University

uu.sePublikasjoner fra Uppsala universitet
Endre søk
RefereraExporteraLink to record
Permanent link

Direct link
Referera
Referensformat
  • apa
  • ieee
  • modern-language-association
  • vancouver
  • Annet format
Fler format
Språk
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Annet språk
Fler språk
Utmatningsformat
  • html
  • text
  • asciidoc
  • rtf
Interactions of GLP-1 peptide analogues with the permeation enhancer sodium caprate: Effect of lipidation and implications for oral delivery
(engelsk)Manuskript (preprint) (Annet vitenskapelig)
Abstract [en]

Oral peptide delivery increasingly relies on permeation enhancers (PEs), but how enhancer self-assembly couples to peptide self-assembly and co-assembly remains poorly understood. Here, we investigated the interactions between glucagon-like peptide-1 (GLP-1) analogues and the permeation enhancer sodium caprate (C10), with emphasis on how peptide lipidation and enhancer self-assembly control peptide availability for absorption. A non-lipidated analogue (J211), two mono-lipidated analogues (J229 and semaglutide), and a bis-lipidated analogue (MEDI7219) were characterized by 1H NMR spectroscopy, diffusion NMR, small-angle X-ray scattering (SAXS), circular dichroism (CD) and all-atom molecular dynamics (MD) simulations. In deuterated buffer, the peptides formed distinct oligomeric states with the size ranking semaglutide > J211 > J229 ≈ MEDI7219, while retaining predominantly α-helical secondary structure. C10 underwent a marked colloidal transition with the formulation conditions, forming non-spherical micelles at pD 8.5 and vesicular aggregates at pD 7.4 in fasted-state simulated intestinal fluid (FaSSIF-V2). Under alkaline micellar conditions, C10 associated with all peptides and remodeled the larger oligomers, J211 and semaglutide, by loosening peptide-peptide packing without major changes in global dimensions or helicity. Under near-neutral biorelevant conditions, peptide-C10 co-assembly became strongly peptide dependent. MEDI7219 showed the weakest association with C10 aggregates and retained the largest unbound fraction, whereas semaglutide and J229 had the most bound fraction. This ranking correlated to previously observed intestinal absorption ranking in vivo. These results show that peptide absorption is impacted by the coupled equilibria between peptide self-assembly, enhancer colloidal state, and peptide bound versus unbound fractions.

Emneord [en]
GLP-1 receptor agonists, sodium caprate, self-assembly, permeation enhancer, Oral peptide delivery
HSV kategori
Forskningsprogram
Farmaceutisk vetenskap
Identifikatorer
URN: urn:nbn:se:uu:diva-595345ISRN: SSRN 7129092DOI: 10.2139/ssrn.7129092OAI: oai:DiVA.org:uu-595345DiVA, id: diva2:2091660
Forskningsfinansiär
Vinnova, 2019-00048Tilgjengelig fra: 2026-08-12 Laget: 2026-08-12 Sist oppdatert: 2026-08-20
Inngår i avhandling
1. Effects of Peptide Molecular Properties and Permeation Enhancement on Oral Absorption
Åpne denne publikasjonen i ny fane eller vindu >>Effects of Peptide Molecular Properties and Permeation Enhancement on Oral Absorption
2026 (engelsk)Doktoravhandling, med artikler (Annet vitenskapelig)
Abstract [en]

Oral delivery of therapeutic peptides remains a pharmaceutical challenge because peptides are susceptible to gastrointestinal degradation and have poor permeability across the intestinal epithelium. Permeation enhancers (PEs), such as sodium caprate (C10), can improve intestinal uptake, but oral bioavailability remains low and variable. Even among structurally related peptides, the extent of absorption may differ following co-administration with the same PE, and the underlying mechanisms remain incompletely understood.

This thesis aimed to determine how peptide molecular properties and interactions with C10 impact intestinal absorption. The translational relevance of used in vitro and ex vivo permeability models were assessed. The effects of backbone modification and lipidation on peptide stability and absorption were studied. Peptide self-assembly, peptide–C10 interactions; and peptide interactions with a model cell membrane were examined. Four GLP-1 peptide analogues were evaluated: non-lipidated J211, mono-lipidated J229 and semaglutide, and bis-lipidated MEDI7219.

Comparative studies in Caco-2 monolayers, rat jejunal Ussing chambers, rats, and pigs showed that C10-mediated enhancement in vivo was concentration dependent and transient. In contrast, the in vitro and ex vivo models did not reproduce this pattern at physiologically relevant C10 concentrations, reflecting limitations including the absence of vascular clearance and epithelial recovery.

In rat intraduodenal studies, C10 significantly increased absorption of four peptides, but the extent varied markedly. MEDI7219 achieved the highest absolute bioavailability (17.3%), compared with 7.5% for J211, 4.0% for J229, and 2.0% for semaglutide. Extensive backbone modification conferred resistance to pancreatin-mediated degradation, whereas semaglutide was degraded. C10 partially improved semaglutide stability, indicating limited protection against luminal proteolysis in addition to enhanced epithelial transport.

Biophysical characterisation and molecular-dynamics simulations showed that the peptides differed in self-association, interaction with C10 aggregates, and membrane engagement. MEDI7219 showed the weakest apparent association with C10 aggregates and retained the highest apparent mobility, consistent with a greater freely available or rapidly exchanging fraction. It also exhibited the deepest and most stable lipid-tail insertion into the model cell membrane. These properties were consistent with its superior intestinal absorption.

C10-enabled oral peptide absorption is governed not only by epithelial permeabilisation, but also by peptide stability, self-assembly, peptide–enhancer interactions, and membrane association.

sted, utgiver, år, opplag, sider
Uppsala: Acta Universitatis Upsaliensis, 2026. s. 115
Serie
Digital Comprehensive Summaries of Uppsala Dissertations from the Faculty of Pharmacy, ISSN 1651-6192 ; 407
Emneord
Permeation Enhancer, Sodium Caprate, Oral Peptide Delivery, Lipidation, GLP-1 Peptide Analogue, Bioavailability
HSV kategori
Forskningsprogram
Farmaceutisk vetenskap
Identifikatorer
urn:nbn:se:uu:diva-596050 (URN)978-91-513-2932-1 (ISBN)
Disputas
2026-10-09, Room IV, University Main Building, Biskopsgatan 3,, Uppsala, 13:15 (engelsk)
Opponent
Veileder
Forskningsfinansiär
Vinnova, 2019-00048
Tilgjengelig fra: 2026-09-17 Laget: 2026-08-20 Sist oppdatert: 2026-09-17

Open Access i DiVA

Fulltekst mangler i DiVA

Andre lenker

Forlagets fullteksthttps://papers.ssrn.com/sol3/papers.cfm?abstract_id=7129092

Søk utenfor DiVA

GoogleGoogle Scholar

doi
urn-nbn

Altmetric

doi
urn-nbn
Totalt: 92 treff
RefereraExporteraLink to record
Permanent link

Direct link
Referera
Referensformat
  • apa
  • ieee
  • modern-language-association
  • vancouver
  • Annet format
Fler format
Språk
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Annet språk
Fler språk
Utmatningsformat
  • html
  • text
  • asciidoc
  • rtf